Scientific Publications
03
Nov
2023
SITC 2023: A miRNA-based shRNA platform for the easy, safe,and effective generation of allogeneic CAR T-cells
03
Nov
2023
SITC 2023: Improvement of CAR T-cell performance by simultaneous downregulation of multiple co-inhibitory receptors
03
Nov
2023
SITC 2023: Proof-of-concept of a non-gene editing technology using shRNA down-regulation to engineer allogeneic CAR T-cells
03
Nov
2023
SITC 2023: NKG2D-based multispecific CAR T-cells to overcome antigen escape andimprove anti-tumor efficacy
03
Nov
2023
SITC 2023: Differential effects of target ligands and receptor architecture upon NKG2D-based CAR T-cell activation
20
Sep
2023
Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform – Mol Ther Nucleic Acids 34:102038
12
Sep
2023
ICLE: Beyond CRISPR: non-gene editing, multiplex gene expression tuning for cell-based immunotherapy
12
Sep
2023
ICLE: Dual-targeting CD19 and NKG2D ligands CAR T-cells are effective against CD19 positive and CD19 negative B cell malignancies
30
Aug
2023
CAR-TCR Summit: Efficient shRNA-based knock-down of multiple target genes for cell therapy using a chimeric miRNA cluster platform
20
Feb
2023
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial – Lancet Haematol. 10(3):e191-e202
05
Oct
2022
Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy – J Immunother. 45(3):150-161
25
Jan
2022
ASCO GI: KEYNOTE-B79 Phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients
13
Dec
2021
ASH: Data from CYAD-02 CYCLE 1 Phase 1 study and CYAD-211 IMMUNICY-1 Phase 1 study
13
Dec
2021
ASH: IMMUNICY-1: Targeting BCMA with CYAD-211 to Establish Proof Of Concept of An shRNA-based Allogeneic CAR T-cell Therapy Platform
12
Nov
2021
SITC: Armoring NKG2D-based CAR T cells with IL-18 improves in vitro and in vivo anti-tumor activity
12
Nov
2021
SITC: A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients
11
Jun
2021
EHA: Objective response at low dose in the first-in-human IMMUNICY-1 trial evaluating non-gene edited allogeneic CYAD-211 anti-BCMA CAR T product in relapsed or refractory multiple myeloma
11
Jun
2021
EHA: Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in r/r MM
15
Jan
2021
ASCO GI: Updated Data from the alloSHRINK Phase 1 First-in-Human Study Evaluating CYAD-101, an Innovative Non-Gene-Edited Allogeneic CAR-T, in Metastatic Colorectal Cancer
24
Dec
2020
Whitepaper – Hairpins and Scissors – Delivering a Non-Gene Edited Allogeneic CAR T Cell Therapy for the Masses
05
Dec
2020
ASH: Results from the Phase I Clinical Studies Evaluating CYAD-01, a first-generation NKG2D CAR T-cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
05
Dec
2020
ASH: Clinical Development of a Non-Gene-Edited Allogeneic BCMA-Targeting CAR T-cell Product in Relapsed or Refractory Multiple Myeloma
05
Dec
2020
ASH: First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating CYAD-02, an Optimized Non-Gene-Edited Engineered NKG2D CAR T-cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
29
May
2020
ASCO: Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T-cells
29
May
2020
ASCO: CYAD-101, an innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy
10
Jan
2020
The integrated stress response promotes B7H6 expression – J Mol Med 98(1): 135–148
09
Dec
2019
ASH: Results from the completed dose escalation of the hematological arm of the phase I THINK study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients
09
Dec
2019
ASH: Interim results from the phase I DEPLETHINK trial evaluating the infusion of a NKG2D CAR T-cell therapy post a non-myeloablative conditioning in relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome patients
09
Dec
2019
ASH: Next generation NKG2D-based CAR-T cells (CYAD-02): Co-expression of a single shRNA targeting MICA and MICB improves cell persistence and anti-tumor efficacy in vivo
09
Dec
2019
Whitepaper – Development of the Next Generation NKG2D CAR T-cell Manufacturing Process
09
Nov
2019
SITC: Results from the completed dose-escalation of the ALLOSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients
09
Nov
2019
SITC: Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients
09
Nov
2019
SITC: Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patients
09
Nov
2019
ICLE: The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy
31
Oct
2019
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies – BioDrugs 33 (5):515-537
16
Sep
2019
ICLE: Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy
05
Jul
2019
World Congress on Gastrointestinal Cancer: Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer
15
Jun
2019
EHA: Development of a next generation allogeneic CAR-T cell platform without gene editing
15
Jun
2019
EHA: Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients
15
Jun
2019
EHA: Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia
18
May
2019
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma – Cancer Immunol Res 7 (1):100-112
03
Dec
2018
ASH: Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy Without a Prior Preconditioning Chemotherapy
03
Dec
2018
ASH: Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia
18
Nov
2018
ESMO-IO: Pooling signaling and costimulatory domains in a flexible CARpool design
18
Nov
2018
SITC: CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule
18
Nov
2018
SITC: Uncovering the phenotype, functional and homing properties of NKG2D CAR T cells
18
Nov
2018
SITC: The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo
09
Nov
2018
SITC: Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors
19
Oct
2018
ESMO: Tackling fratricide to manufacture clinical grade NKG2D‐CAR T cells for cancer therapy
19
Oct
2018
ESMO: Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Metastatic Colorectal Cancer
19
Oct
2018
ESMO: The high expression of NKG2D ligands on tumor and non‐tumor cells and a lack of surface expression on healthy tissues provide a strong rationale to support NKG2D‐based therapeutic approaches for cancer.
01
Jul
2018
Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressingT cells for autologous adoptive cell therapy – Cytotherapy 20(7):952-963
19
May
2018
ASGCT: Early signs of clinical activity of NKG2D CAR-T cell (CYAD-01) activity in AML patient
16
May
2018
ASGCT: Expression of a TIM peptide reduces alloreactivity of T cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T cell therapy approach
16
May
2018
ASGCT: Functional screening of an anti-B7H6 specific chimeric antigen receptor (CAR)
27
Apr
2018
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient – Haematologica 103(9):e424-e426
17
Apr
2018
AACR: The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D Chimeric Antigen Receptor T cell therapy (CYAD-01) in acute myeloid leukemia
17
Apr
2018
AACR: NKG2D as a chimeric antigen receptor – DAP10 provides optimal co-stimulation for NKG2D-based CARs
17
Apr
2018
AACR: A Phase 1 study assessing the safety and clinical activity of multiple doses of an NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer
17
Apr
2018
AACR: A Phase 1 study assessing the safety and clinical activity of multiple hepatic transarterial administrations of an NKG2D-based CAR-T therapy, CYAD-01, in patients with unresectable liver metastases from colorectal cancer
04
Apr
2018
Celyad’s novel CAR T-cell therapy for solid malignancies – Curr Res Transl Med 66(2):53-56
14
Nov
2017
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types – BMJ Open 7(11):e017075
01
Sep
2017
ESMO: A Phase I Global Trial Targeting Multiple Solid and Hematologic Malignancies through a NKG2D receptor-based CAR-T Immunotherapy
01
Aug
2017
‘Atypical’ CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors – Immunotherapy 9(9):723-733
05
Jun
2017
ASCO: A NKG2D-based CAR-T therapy in a Multinational Phase 1 Dose Escalation and Expansion Study Targeting Multiple Solid and Hematologic Tumor Types
31
Mar
2017
Exploiting natural killer group 2D receptors for CAR T-cell therapy – Future Oncol 13(18):1593-1605
06
Dec
2016
CAR-TCR: Safety Data from a First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma
13
Sep
2016
ASH: Safety Data from a First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma
04
Jun
2016
ASCO: A First-in-Human Phase I Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma